BAT Testing Evidence Matrix

BAT Testing Matrix

This page provides representative studies behind blood-based biomarker science used in BAT Testing educational context. It is a curated sample and not an exhaustive list of all reviewed literature.

The focus is on how Beta-Amyloid and Tau biomarker evidence evolved over time, and how longitudinal trend interpretation became central to monitoring frameworks.

1906-2000 Evidence Scan

Over 31,000 studies on Alzheimer's disease, amyloid, tau, and related biomarkers were published between 1906 and 2000. This period began with Alois Alzheimer's early pathology observations and expanded through decades of neuroscience, genetics, and molecular biology research on Beta-Amyloid and Tau biology. Methodological advances in immunohistochemistry, protein quantification, and early imaging enabled increasingly reliable measurement of these markers in brain tissue and cerebrospinal fluid. Together, this foundational work informed the later development of blood-based BAT TESTING™ workflows.

Alois Alzheimer / historical review (2003)

Historical review of initial disease characterization and early pathology framing.

Fischer (1907)

Early plaque-pathology observations in senile dementia.

Glenner & Wong (1984)

Biochemical characterization of beta-amyloid in plaque core material.

Blennow et al. (1995)

CSF tau signal work that supported later biomarker panel development.

2001-2005 Evidence Scan

Over 23,600 studies on amyloid, tau, and earlier biomarker science were published from 2001 to 2005. This period expanded clinical validation of sensitive CSF assays for Beta-Amyloid and Tau and strengthened links between molecular biomarker patterns and longitudinal clinical outcomes. The introduction of amyloid PET imaging enabled in vivo visualization of amyloid pathology in living participants. Together, these advances reinforced Beta-Amyloid and Tau as core biomarker targets and informed later BAT TESTING™ development.

Blennow et al. (2001)

Combined Aβ42 and tau biomarker utility in clinical context.

Clark et al. (2003)

Early amyloid imaging advances enabling in vivo plaque visualization.

Andreasen et al. (2001)

Biomarker shifts associated with conversion patterns over time.

Riemenschneider et al. (2002)

Panel-level diagnostic-separation performance in clinical cohorts.

2006-2010 Evidence Scan

Between 2006 and 2010, more than 27,700 studies accelerated translation from laboratory methods toward clinical workflows. Improved PET tracers, including Pittsburgh Compound B (PiB), supported larger-scale amyloid imaging studies, while immunoassay advances improved Beta-Amyloid and Tau measurement consistency. International consortia also strengthened protocol standardization and cross-center data comparability. Together, these developments helped prepare the evidence environment for later biomarker-driven BAT TESTING™ adoption.

Tapiola et al. (2009)

CSF Aβ42/tau patterns correlated with pathology-confirmed outcomes.

De Meyer et al. (2010)

Multicenter cut-off standardization for biomarker interpretation.

Fagan et al. (2007)

Low CSF Aβ42 associated with amyloid PET positivity and later trends.

Mattsson et al. (2009)

Multicenter cohorts supporting prognostic utility of combined biomarkers.

2011-2015 Evidence Scan

During 2011 to 2015, over 41,000 studies advanced the brain biomarker landscape. This period included early clinical validation work on blood-based Beta-Amyloid and phosphorylated Tau (pTau) assays, alongside comparisons with CSF and PET reference methods. Major longitudinal cohorts strengthened the case for earlier biomarker-informed monitoring, and evolving research criteria increased integration of blood-marker context into broader clinical frameworks. Together, these developments expanded access to earlier trend tracking and follow-up planning.

Sperling et al. (2011)

NIA-AA framework formalizing preclinical biomarker-stage research context.

Dubois et al. (2014)

Revised criteria integrating biomarker evidence in research settings.

Mattsson et al. (2011)

Large cohort utility of CSF marker combinations in progression studies.

2016-2020 Evidence Scan

From 2016 to 2020, more than 58,400 studies on BAT-related biomarkers and earlier monitoring approaches expanded the evidence base. Ultra-sensitive plasma assays for Aβ42/40 and pTau181 were further developed and validated, supporting noninvasive and more scalable blood-based workflows. Multicenter studies strengthened confidence in longitudinal biomarker tracking across diverse populations, and clinical adoption began to increase. This period helped establish BAT TESTING™ as a practical tool for proactive brain health monitoring over time.

Janelidze et al. (2016)

Biomarker classification work bridging fluid and imaging signals.

Hansson et al. (2018)

Multicenter validation of plasma Aβ and pTau marker use in clinical settings.

Schindler et al. (2019)

High-precision plasma Aβ42/40 work associated with amyloid-pathology signals.

Palmqvist et al. (2019)

Plasma Aβ42/40 and APOE context improving accessible biomarker models.

2021-2024 Evidence Scan

Over 76,000 studies published between 2021 and 2024 expanded the clinical discussion around blood-based BAT TESTING™. This period emphasized real-world evidence from BATWatch and other initiatives, showing how repeat blood measurements of Beta-Amyloid and pTau181 can support longitudinal brain health monitoring at scale. In this framework, BAT TESTING™ is used as a front-line measurement tool for tracking biological drift patterns over time and informing provider-guided follow-up.

Verberk et al. (2021)

Clinical-utility studies of plasma Aβ42/40 and p-tau markers.

Benedet et al. (2022)

Plasma p-tau/Aβ associations with PET-confirmed amyloid patterns.

Janelidze et al. (2022)

Plasma pTau and Aβ combinations supporting high-accuracy early biomarker classification.

Fogelman et al. (2023)

Blood biomarker probability scores associated with amyloid pathology and clinical outcomes.

Related Pages

BAT Testing

Term and workflow overview for measurement context.

BATCheck

Check-in and report-layer context for interpretation.

BATReset Matrix

mTOR/autophagy-focused management evidence scan.